Friday 6 November 2026 Export RPRX’s income statement to Excel — free account

Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue: +13.3%
EPS: −51.5%
Free cash flow: +364.6%
Total debt: −4.00%

Quarter to September 2026, against a year earlier

Dividend growth 5 yrs

67.59 0.02 +0.03%

Follow RPRX

Alert me

Market cap: $39.0B
P/E: 44.8×
Fwd P/E: 27.3×
Dividend yield: 1.37%
F-score: 5/9
Altman Z: 1.61
Beneish M: −2.83
Dividend safety: 41/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

	Sep '26 From the 10-Q filed 4 Nov	Jun '26	Mar '26	Dec '25	Older periods
P/E ratio Full definition →	38.65	30.31	25.25	21.71	+8 more quarters Free account
P/S ratio Full definition →	9.95	9.84	8.59	6.98
P/FCF ratio Full definition →	20.12	19.05	17.53	4.72
P/Operating CF Full definition →	37.94	34.26	29.17	20.08
P/B ratio Full definition →	2.66	2.55	2.11	1.71
Price to Tangible BV Full definition →	2.93	2.82	2.32	1.89
EV/Sales Full definition →	13.02	13.04	12.01	10.48
EV/EBITDA Full definition →	22.02	21.38	18.04	15.65
EV/Operating CF Full definition →	11.51	11.11	11.22	10.01
EV/FCF Full definition →	26.34	25.25	24.51	7.09
Quick Ratio Full definition →	0.46	1.38	1.19	1.05
Current Ratio Full definition →	1.29	2.80	2.66	2.40
Net Debt/EBITDA Full definition →	0.00	57.16	14.60	20.93
Debt/Assets Full definition →	44.13%	45.22%	45.20%	45.62%
Debt/Equity Full definition →	0.88	0.92	0.90	0.92
Asset Turnover Full definition →	0.13	0.13	0.13	0.13
Operating CF/Net income Full definition →	0.00	40.73	2.44	3.92
Capex/Depreciation Full definition →	—	(27.81)	(51.17)	0.00
Interest Coverage Full definition →	4.54	1.42	6.01	4.12
Research and Development Expense of Revenue Full definition →	9.15%	14.51%	6.31%	8.12%
Selling, General and Administrative Expense of Revenue Full definition →	21.75%	24.01%	25.29%	26.41%
Intangible Assets out of Total Assets Full definition →	0.05	0.05	0.05	0.05
Share Based Compensation of Revenue Full definition →	15.20%	15.88%	19.35%	20.22%
Graham Net Nets Full definition →	(0.31)	(0.33)	(0.40)	(0.50)
Graham Number Full definition →	27.32	30.25	31.19	30.09
Earnings Yield Full definition →	2.59%	3.30%	3.96%	4.61%
Free Cash Flow Yield Full definition →	4.97%	5.25%	5.71%	21.18%
Revenue per Share Full definition →	1.55	1.51	1.44	1.45
Operating CF per Share Full definition →	1.54	1.64	1.64	1.92
Capex per Share Full definition →	0.00	(0.56)	(1.04)	0.00
Free Cash Flow per Share Full definition →	1.54	1.07	0.61	1.92
Cash per Share Full definition →	1.22	1.88	1.39	1.48
Shareholders Equity per Share Full definition →	21.96	21.99	22.75	22.60
Interest Debt per Share Full definition →	0.00	0.00	0.00	0.00
Book value per Share Full definition →	21.96	21.99	22.75	22.60
Free Cash Flow Full definition →	686.08	477.44	265.87	827.15
Working Capital Full definition →	346.56	1,133.64	890.13	891.88
Capital Expenditures Full definition →	—	(251.02)	(452.37)	—
Net Current Asset Value Full definition →	(8,140.38)	(8,269.49)	(8,452.77)	(8,377.75)
EV/EBIT Full definition →	22.79	21.88	18.45	15.98
Capex to Sales Full definition →	0.00	0.37	0.72	0.00
Price to Operating Income Full definition →	17.41	16.51	13.19	10.65
Other line items
Average Receivables Full definition →	—	29.61	25.65	28.14
Average Payables Full definition →	36.42	27.89	31.56	16.39
Average Assets Full definition →	19,404.25	19,071.39	18,711.84	18,921.75
Average Common Equity Full definition →	9,708.07	9,644.33	9,862.75	10,028.65

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026

Stockrow Weekly